Over the past 12 months, the application of generative AI (GenAI) in the Medical Instruments industry has moved from experimental to operational use, enhancing diagnostics, patient monitoring and intervention workflows. GenAI could transform health care through synthetic medical imaging, disease progression modeling sand drug molecule design with simulated effect, according to a 2025 U.S. National Science Foundation report. At the same time, regulatory bodies are adapting. The European Union AI Act (EU AI A ...

Industry Overview - The U.S. medical instrument industry has stabilized entering 2026 after years of volatility due to inflation, rising interest rates, and uneven hospital spending, with procedure volumes normalizing post-pandemic [1] - Providers are cautious on capital budgets, focusing on productivity, reliability, and total cost of ownership [1] - The Medical - Instruments industry is ranked in the top 35% of the Zacks Industry Rank, indicating expected outperformance over the next three to six months [2] Company Highlights Intuitive Surgical Inc. (ISRG) - ISRG is integrating AI and digital tools into its robotic ecosystem, enhancing surgical performance metrics and providing real-time decision support [4][5] - The company has an expected revenue growth rate of 14.9% and earnings growth rate of 12.7% for the current year, with a Zacks Consensus Estimate for earnings improving by 0.5% [6] - The short-term average price target indicates a potential increase of 26% from the last closing price of $493.56, with a maximum upside of 52% [8] Globus Medical Inc. (GMED) - GMED's acquisition of Nevro and the merger with NuVasive are expected to strengthen its position in the musculoskeletal space and expand its product portfolio [9][10] - The company anticipates revenue growth of 8% and earnings growth of 7.5% for the current year, with earnings estimates improving by 6.7% [10] - The short-term average price target suggests a 24.7% increase from the last closing price of $87.81, with a maximum upside of 40.1% [11] Edwards Lifesciences Corp. (EW) - EW's Surgical Structural Heart business is benefiting from strong adoption of premium surgical technologies, with a focus on developing a comprehensive structural heart disease portfolio [12][13] - The expected revenue growth rate is 9.6% and earnings growth rate is 14.8% for the current year, with earnings estimates improving by 2.1% [14] - The short-term average price target indicates a 14% increase from the last closing price of $84.26, with a maximum upside of 30.5% [14] Alcon Inc. (ALC) - ALC is leveraging its Surgical and Vision Care segments for growth, with innovative products driving category leadership [15][16] - The expected revenue growth rate is 7.1% and earnings growth rate is 12.1% for the current year, with earnings estimates improving by 2.1% [16] - The short-term average price target suggests a 13.9% increase from the last closing price of $81.85, with a maximum upside of 36.8% [17] IRADIMED Corp. (IRMD) - IRMD specializes in MRI-compatible products and serves hospitals and outpatient imaging centers [18][19] - The expected revenue growth rate is 10.8% and earnings growth rate is 8.8% for the current year, with earnings estimates remaining stable [20] - The short-term average price target indicates a 19.9% increase from the last closing price of $100.18, with a maximum upside of 20% [20]

Core Viewpoint - Waters (WAT) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [1]. - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [4]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [4]. Improvement in Business Outlook - The rising earnings estimates and the Zacks rating upgrade for Waters suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [5]. - Over the past three months, the Zacks Consensus Estimate for Waters has increased by 1%, with expected earnings of $14.40 per share for the fiscal year ending December 2026, indicating no year-over-year change [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Waters to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Insights - QuidelOrtho (QDEL) has entered a long-term strategic supply agreement with Lifotronic Technology to enhance its global immunoassay portfolio, gaining access to over 70 assays and multiple analyzer platforms [1][6][8] Company Developments - The agreement addresses key menu gaps for QuidelOrtho, strengthening its position in full-service laboratory tenders across Europe, Asia-Pacific, and Latin America [2][4] - The partnership is expected to add more than 25 new assays not currently available on QuidelOrtho's VITROS systems, enhancing its competitive edge in various laboratory settings [6][8] - QuidelOrtho reported Q4 2025 revenues of $723.6 million, reflecting a 2.2% year-over-year increase, with adjusted earnings per share of 46 cents [8][12] Market Position and Trends - QuidelOrtho's market capitalization stands at $1.6 billion, and its stock has gained 3.4% over the last six months, outperforming the industry which declined by 6.9% [5][3] - The global immunoassay analyzers market is projected to grow from $7.2 billion in 2024 to $9.2 billion by 2030, with a CAGR of 4.1% driven by the rising prevalence of chronic diseases [10] - The collaboration with Lifotronic is expected to drive recurring reagent revenue and enhance international revenue diversification, supporting stable growth outside the U.S. market [7]

Core Insights - Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 59 cents for Q4 2025, a decline of 22.4% year over year, and missed the Zacks Consensus Estimate by 9.2% [1][7] - The company’s total revenues for Q4 were $977.2 million, a slight decrease of 0.2% year over year, but exceeded the Zacks Consensus Estimate by 1.12% [3][10] - For the full year 2025, adjusted EPS was $1.83, down 24.1% from the previous year [2] Revenue Analysis - Q4 revenues by geography showed a 13.8% decline in the U.S. to $225 million, while Europe saw a 1% increase to $377 million, and Asia Pacific revenues rose 8.3% to $301.2 million [4] - The BSI BioSpin segment revenues fell 2% to $267 million, while BSI CALID revenues increased by 3.4% to $331.6 million [4] - Total revenues for 2025 reached $3.44 billion, reflecting a 2.1% increase from the previous year [3] Margin Performance - Gross profit decreased by 8.9% to $449.2 million, with gross margin contracting by 439 basis points to 46% due to an 8.6% rise in the cost of revenues [5][10] - Adjusted operating profit was $102.4 million, down 27.7% year over year, with adjusted operating margin contracting by 398 basis points to 10.5% [5] Financial Position - At the end of Q4 2025, Bruker had cash and cash equivalents of $298.8 million, an increase from $183.4 million at the end of 2024 [6] - Long-term debt at the end of Q4 2025 was $1.87 billion, down from $2.09 billion at the end of Q4 2024 [8] 2026 Guidance - Bruker provided guidance for 2026, expecting revenues between $3.57 billion and $3.60 billion, indicating a year-over-year growth of 4% to 5% [9] - Adjusted EPS for 2026 is projected to be in the range of $2.10 to $2.15, representing an increase of 15% to 17% year over year [9] Overall Assessment - The company ended Q4 2025 with mixed results, as earnings missed estimates while revenues surpassed them [10] - Margins were negatively impacted by lower volume, unfavorable mix, tariffs, and currency headwinds [10] - Despite challenges, Bruker’s innovation efforts showed promise, with expectations for improved contributions from the BEST segment in 2026 [11]

Core Insights - Waters Corporation (WAT) reported fourth-quarter 2025 non-GAAP earnings of $4.53 per share, exceeding the Zacks Consensus Estimate by 0.67% and reflecting a year-over-year increase of 10.5% [1] - Net sales reached $932.4 million, surpassing the Zacks Consensus Estimate by 0.55%, with a reported increase of 7% and a 6% increase on a constant currency basis year over year [1] Segment Performance - The Waters segment generated sales of $823.9 million, up 8% on a reported basis and 7% on a constant currency basis year over year, while the TA segment reported sales of $108.4 million, remaining flat year over year [2] - Instrument sales were $432.9 million, up 3% year over year, Services sales were $329.1 million, increasing 9% year over year, and Chemistry sales were $170.3 million, growing 13% year over year [3] Market Performance - The Pharmaceutical market generated sales of $540.6 million, an 8% increase year over year, while Industrial sales were $284.5 million, also up 8% year over year. Government & Academic sales decreased by 2% to $107.3 million [4] - Sales in Asia reached $283.9 million, up 4% reported and 11% at constant currency, while the Americas reported sales of $332.4 million, increasing 4% in both reported and constant currency terms. Europe generated sales of $315.9 million, a 13% increase reported and 4% at constant currency [5] Operating Details - Non-GAAP selling and administrative expenses were $191 million, up 13.3% year over year, with an increase of 120 basis points as a percentage of net sales. Research and development expenses were $50.1 million, up 8.3% year over year [6] - The adjusted operating margin was 35.2%, contracting by 20 basis points year over year [6] Financial Position - As of December 31, 2025, cash and cash equivalents were $587.8 million, up from $459.1 million as of September 27. The company generated cash from operations of $164.5 million and reported a free cash flow of $125.2 million [7] Guidance - Waters expects first-quarter 2026 sales growth between 7% and 9% on a constant currency basis, with organic reported sales projected between $718 million and $731 million, and full-year sales expected between $3.35 billion and $3.40 billion [8][9] - Non-GAAP earnings for the first quarter are anticipated to be in the range of $2.25 to $2.35 per share, indicating year-over-year growth of approximately 0.0% to 4.4% [9]

Company Overview - Revvity, Inc. is headquartered in Waltham, MA, and provides scientific instruments, consumables, and services to various markets including pharmaceutical, biomedical, environmental testing, chemical, and general industrial sectors. The company was previously known as PerkinElmer until March 2023 [11]. Recent Developments - In March 2023, Revvity completed the sale of its Applied, Food and Enterprise Services (AES) businesses to New Mountain Capital for up to $2.45 billion. Following this divestiture, the company changed its name to Revvity effective April 26, 2023, and its ticker symbol changed from PKI to RVTY on May 16, 2023 [11]. Stock Performance - Revvity (RVTY) currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B. The stock has a Momentum Style Score of A, and shares have increased by 4.9% over the past four weeks [12]. - Two analysts have revised their earnings estimates upwards for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.02 to $5.33 per share. Revvity has an average earnings surprise of +4.1% [12]. Investment Consideration - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Revvity is recommended to be on investors' short list for potential investment opportunities [13].

Core Insights - The U.S. medical instrument and medtech sector is stabilizing as it enters 2026, with normalized procedure volumes post-pandemic and a focus on productivity and cost management [1][3] - Companies that can demonstrate operational improvements and earnings visibility are favored in the current investment environment, despite modest top-line growth [1][6] U.S. Macro Trends - Medtech equities are influenced by U.S. macroeconomic factors, particularly the Federal Reserve's interest rate policy, which is currently targeted between 3.5% and 3.75% [3] - Elevated labor and materials inflation rates have moderated, impacting margins more than demand, as companies align pricing and productivity with cost structures [4] Hospital Dynamics - U.S. hospitals are managing tight capital budgets while maintaining steady procedure volumes, benefiting companies with strong service and consumables revenue rather than those reliant on large equipment sales [5] - Staffing shortages are driving hospitals towards automation and efficiency, creating opportunities for device manufacturers offering productivity-enhancing solutions [5] Investment Opportunities in Undervalued Stocks - Undervalued medtech stocks may outperform through earnings recovery and multiple re-rating, as historical periods of uncertainty often compress valuations [6][7] - "Undervalued" stocks are defined as those trading below their historical valuation ranges, with potential for earnings growth through operational leverage and cost-reduction initiatives [7] Company-Specific Insights Fresenius Medical Care (FMS) - FMS is experiencing margin recovery due to cost savings and pricing improvements, with a current P/S F12M of 0.55x, below its 5-year median of 0.63x [10][11] - The company reported a rise in operating margin to 11.7% for Q3 2025, supported by cost savings and disciplined execution, with an expected earnings growth of 9% in 2026 [11][13] Integra LifeSciences (IART) - IART operates in neurosurgery and surgical instruments, currently trading at a P/S F12M of 0.59x, below its 5-year median of 2.14x [14][15] - The company anticipates supply normalization and margin expansion initiatives targeting $25-$30 million in savings, with expected earnings growth of 5.5% in 2026 [15][16] STERIS (STE) - STERIS provides sterilization services and is currently trading at a P/S F12M of 4.23x, slightly above its 5-year median of 3.97x [18][19] - The company reported high-single-digit organic revenue growth and expanded EBIT margin to 23.1%, with an expected earnings growth of 8.6% in 2026 [19][21]

Core Insights - The application of generative AI in the Medical Instruments industry has transitioned from experimental to operational, enhancing diagnostics, patient monitoring, and intervention workflows [1] - The global AI in healthcare market is projected to grow at a CAGR of 44% from 2025 to 2032, despite facing geopolitical challenges [2] - The medical instruments industry is highly fragmented, with significant trends including AI integration, telemedicine expansion, and robotic-assisted surgeries [3] Industry Trends - **Generative AI Adoption**: The medical instruments sector is experiencing a surge in generative AI adoption, with a focus on hyper-personalization and predictive treatment options. The global generative AI market in healthcare is valued at $2.64 billion in 2025, expected to grow at a CAGR of 35.2% through 2034 [4] - **M&A Activity**: The industry is witnessing a robust M&A trend, with MedTech deal value reaching $92.8 billion in 2025, driven by major acquisitions such as Abbott's $23 billion deal for Exact Sciences [5] - **Business Disruption**: Global growth is projected to remain subdued, with the IMF forecasting growth rates of 3.2% in 2025 and 3.1% in 2026, below pre-pandemic averages [6][7] Performance Metrics - The Zacks Medical Instruments industry currently holds a Zacks Industry Rank of 161, placing it in the bottom 33% of 243 Zacks industries, indicating poor near-term prospects [8] - The industry has underperformed the S&P 500 and broader sector over the past year, with a growth of 3.1% compared to the sector's 6.9% and the S&P 500's 19.3% [10] - The industry is trading at a forward P/E of 30.36X, higher than the broader industry average of 21.29X and the S&P 500's 23.42X [13] Company Highlights - **Veracyte**: A global cancer diagnostics company with a projected 2025 sales estimate of $508.6 million, reflecting a 14.1% increase from 2024 [18][19] - **IDEXX Laboratories**: Focused on veterinary and livestock testing, with a 2025 sales estimate of $4.28 billion, indicating a 9.9% rise from 2024 [21][22] - **Intuitive Surgical**: Specializes in minimally invasive care, with a 2025 sales estimate of $9.92 billion, suggesting an 18.7% increase from 2024 [25][26]

Core Insights - The replacement cycle for instruments has been ongoing for about a year, with significant momentum observed in orders outpacing revenues [1][2] - The growth rate for LC-MS instruments remains in the high single-digit range, driven by the replacement cycle and other factors [2][3] - The industry is still in the early stages of the replacement cycle, with many customer segments yet to begin replacing their instruments [3] Group 1 - The instrument replacement cycle is expected to continue, indicating a positive trend for future growth [3] - Current growth for LC-MS instruments is characterized by a low single-digit CAGR over the past six years, suggesting room for improvement [3] - The sales funnel for instruments is strong, indicating good future demand [3]